Latest Advances in Lung Cancer Research

Lack of Adherence to Treatment Guidelines for NSCLC patients was found in nearly one third of patients in a recent study.

Artificial intelligence blood test to detect lung cancer. Researchers developed novel technology to detect lung cancer in patients.

Five Year Lung Cancer Survival Update: Pembrolizumab continued to improve OS than docetaxel in patients with PD-L1 TPS ≥50% and TPS ≥1%.

Liquid biopsy simpler sampling: Liquid biopsies are easier on patients, yield faster results and cost less than tissue biopsies.

Address disparities in lung cancer screening. Abstracts presented at ASCO’s 2021 annual meeting address disparities in lung cancer screening.

Future of liquid biopsy: Analysis of tumours using biomarkers in blood is beginning to transform cancer diagnosis.

Bone marrow damage reduced for extended stage small cell lung cancer patients with newly FDA approved Cosela.

Lower risk of brain mets from screening. LDCT Screening linked to lower risk of brain mets for lung cancer patients.

Imfinzi increases five year survival to 43% in patients with Stage III non-small cell lung cancer. After treatment, 43% survive 5+ years.

Dr. Karen Marrone discusses the role of postoperative radiotherapy (PORT) in early-stages of non-small cell lung cancer (NSCLC).

Diverse workforce in oncology: Improvement of inclusion and equity critical to reducing health disparities in cancer care.

No link to outside article.